PharmaBoardroom

Merck’s EUR 250 Million Investment in New Swiss Biotech…

German biopharma giant Merck is investing EUR 250 million in a new Swiss biotech development facility; underscoring the company’s reliance on…

Roman Badik – CEO, Enantis, Czech Republic

Roman Badik, CEO of Enantis, the first biotechnology spin-off from Masaryk University in the Czech Republic, shares his vision of turning the…

China Biosimilar Market Snapshot

Biosimilars are a relatively recent development in the pharmaceutical industry, meaning market penetration is still fairly low, even in many developed…

UK Biotech Snapshot 2019

A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing…

2019 A Boom Year for UK Biotech, Despite Brexit Concerns

Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry's…

Yuguang Wang – CEO, Maxinovel Pharmaceuticals, China

Dr Yuguang Wang, CEO of Maxinovel Pharmaceuticals, recaps his three decades of industry experience across Big Pharma, biotech and CRO organizations in…

Chinese Biotechs Flock to IPO in Hong Kong

2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating…

Global Pharma has Reinvented R&D: Will Canadian Start-Ups…

John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global…

Hot Topics in Chinese Biotech

PharmaBoardroom sat down with more than 25 biotech CEOs in China in 2019. We analyzed the contents of the interviews and found the following recurring…